| 000 | 00854 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250513173010.0 | ||
| 264 | 0 | _c19940825 | |
| 008 | 199408s 0 0 eng d | ||
| 022 | _a1170-7690 | ||
| 024 | 7 |
_a10.2165/00019053-199405020-00002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarber, A M | |
| 245 | 0 | 0 |
_aBenefits versus profits: has the orphan drug act gone too far? _h[electronic resource] |
| 260 |
_bPharmacoEconomics _cFeb 1994 |
||
| 300 |
_a88-92 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOrphan Drug Production _xeconomics |
| 650 | 0 | 4 | _aUnited States |
| 773 | 0 |
_tPharmacoEconomics _gvol. 5 _gno. 2 _gp. 88-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00019053-199405020-00002 _zAvailable from publisher's website |
| 999 |
_c10106445 _d10106445 |
||